Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01788904
Other study ID # FARAMIS 2013
Secondary ID
Status Recruiting
Phase N/A
First received February 7, 2013
Last updated December 11, 2013
Start date February 2013
Est. completion date June 2017

Study information

Verified date December 2013
Source University Hospital Regensburg
Contact Peter G Heiss, MD, MS
Phone +49 941 944 7401
Email peter.heiss@ukr.de
Is FDA regulated No
Health authority Germany: Local Independent Ethics Committee at Regensburg University
Study type Observational

Clinical Trial Summary

In the FARAMIS study, we aim to investigate the longitudinal course of intestinal plasma fatty acid binding protein (i-FABP) in patients with acute mesenteric ischemia (AMI) undergoing primary percutaneous angiographic intervention.

The investigators postulate that patients with fully re-established intestinal blood flow and vital intestines will display a significant drop of plasmatic i-FABP within 24 hours, while patients requiring subsequent intestinal resection due to irreversible bowel necrosis will not.

If true, patients requiring laparotomy and bowel resection could be identified and patients in whom angiographic intervention led to successful cure of disease would not be exposed to potentially perilous surgery.


Description:

Intestinal plasma fatty acid binding proteins (i-FABP) have been introduced as a powerful marker for the diagnosis of intestinal ischemia. Based on several small studies, this marker is referred to as a sensitive indicator for intestinal ischemia. I-FABP is characterized by its short half-time of eleven minutes in blood circulation, which might allow "real-time" monitoring of necrotic intestinal segments.

Subjects meeting the in-/exclusion criteria will undergo five to six blood collections: one baseline assessment before revascularization, three assessments directly after angiographic intervention (5/30/120 minutes), and one assessment after 24 hours. An additional blood collection will be performed in patients who underwent subsequent surgery. In addition, clinical exams of the patient are carried out.

Subjects will be observed for 72 hours after percutaneous revascularization and retrospectively classified depending on the clinical course: recovering patients or patients undergoing surgery without signs of necrotic segments will be attributed to group A. Patients in whom intestinal necrosis is confirmed by surgery or autopsy will belong to group B. For all patients, clinical and laboratory findings will be reported in a descriptive manner.

To evaluate whether the post-interventional course of plasmatic i-FABP is a reliable predictor for successful revascularization, the minimum level of i-FABP at the time points 5, 30 and 120 Minutes is divided by the baseline (= before intervention) level of i-FABP. This ratio (R) reflects the decrease (or increase) of i-FABP after revascularization. Receiver operating characteristic (ROC)-analysis will be carried out and the area under the curve will be determined for different R-values (e.g. 0.3, 0.5, 0.7).

We postulate that patients with fully re-established intestinal blood flow and vital intestines will display a significant drop of plasmatic i-FAPB within 24 hours, while patients requiring subsequent intestinal resection due to irreversible bowel necrosis will not.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Presence of acute mesenteric ischemia due to stenosis of the superior mesenteric artery, thromboembolization of the superior mesenteric artery, non-occlusive mesenteric ischemia or acute portal vein thrombosis (as confirmed by CT scan)

- The vascular anatomy is suitable for percutaneous revascularization

- A primary endovascular re-vascularisation approach is intended based on an interdisciplinary decision by the visceral surgeon, the vascular surgeon and interventional radiologist. This therapeutic decision is made independently of the proposed FARAMIS study.

- A peripheral or central line is present to perform repeated blood collections

Exclusion Criteria:

- Clinically or imaging results indicating that perforation of the bowel is present or suspected

- Hemodynamic instability (shock)

- Pre-existing severe liver or kidney damage (defined as spontaneous international normalized ratio >2 or creatinine >2 mg/dl.)

- Anemia with hemoglobin concentration < 7g/dl

- Pediatric patients

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Germany University Hospital Regensburg Regensburg

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Regensburg William Cook Europe

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Levels of i-FABP, interleukine 6 and 8 Association of increased levels of i-FABP, interleukine 6 and 8 with extension of intestinal necrosis according to the pathology report and occurrence of organ failure 72 hours No
Primary Post-interventional course of plasmatic i-FABP as reliable predictor for successful bowel revascularization Subjects will be observed for 72 hours after percutaneous revascularization. Patients will then be divided into two groups: patients not requiring surgery and not dying from intestinal necrosis will be allocated to group A. Subjects who undergo surgery without signs of necrotic segments will also be attributed to group A. Patients in whom intestinal necrosis is confirmed by surgery or autopsy will belong to group B.
To evaluate whether the post-interventional course of plasmatic i-FABP is a reliable predictor for successful revascularization, the minimum level of i-FABP at the time points 5, 30 and 120 Minutes is divided by the baseline (= before intervention) level of i-FABP. This ratio (R) reflects the decrease (or increase) of i-FABP after revascularization. ROC-analysis will be carried out and the area under the curve will be determined for different R-values.
72 hours No
Secondary Baseline level of i-FABP as predictor of bowel necrosis 72 hours No
See also
  Status Clinical Trial Phase
Recruiting NCT05194527 - The Detrimental Course of Acute Intestinal Ischemia
Not yet recruiting NCT06387147 - ORal Antibiotics In Acute Mesenteric Ischemia Phase 3
Completed NCT04867499 - Epidemiology of Acute Mesenteric Ischemia
Not yet recruiting NCT06212921 - Biomarkers in Prediction of AMI N/A
Recruiting NCT03518099 - Searching Biomarkers of Acute Intestinal Ischemic Injuries N/A
Not yet recruiting NCT06428240 - Acute Mesenteric Ischemia, Reality in Catalonia
Active, not recruiting NCT06365827 - Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI)
Recruiting NCT06445660 - The Feasibility of a Radiological Score Based on CT Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia
Completed NCT05218863 - Incidence, Diagnosis, Management and Outcome of Acute Mesenteric Ischemia
Completed NCT05706012 - Antithrombotic Management of Acute Mesenteric Ischaemia
Not yet recruiting NCT06310395 - Analysis of the Acute Mesenteric Ischemia in a Single Institution Over 10 Years
Completed NCT05665946 - Acute Intestinal Necrosis- the Preoperative Diagnostic Approach
Recruiting NCT02772913 - Mesenteric Ischemia in the Emergency Department: a Retrospective Multicenter Study N/A